Title: Methylated septin 9 gene is an important prognostic marker in stage II and stage III
colorectal cancer for evaluating local recurrence or distant metastasis after surgery
Version: 1 Date: 15 Nov 2021
Reviewer's report:
Major points
1) 2.1 Patients, line 2. Two-year DFS has been analyzed even though the end of the case
enrollment period is January 2020, which is less than two years. The Median follow up period
should be indicated. Also, in Figure 4, Patients at risk should be shown.
2) The Adjuvant chemotherapy regimen should be stated. It is not common to perform advanced
chemotherapy in all Stage II cases.
3) Tables 1, 2, 3. Not only the classification of Colon and Rectum, but also the sideness of colon
should be classified.
4) Table 2. It is strange that colon and rectum are not prognostic factors.
5) Discussion. From Table 1, mSEPT9 and microsatellite status seem to be closely related, but
that is not discussed.
6) Discussion. The limitation of this study is not mentioned.
Minor point
7) 2.1 Patients, exclusion criteria, (III). No adjuvant treatment # neoadjuvant treatment
Title: Methylated septin 9 gene is an important prognostic marker in stage II and stage III
colorectal cancer for evaluating local recurrence or distant metastasis after surgery
Version: 1 Date: 15 Nov 2021
Reviewer's report:
Major points
1) 2.1 Patients, line 2. Two-year DFS has been analyzed even though the end of the case
enrollment period is January 2020, which is less than two years. The Median follow up period
should be indicated. Also, in Figure 4, Patients at risk should be shown.
2) The Adjuvant chemotherapy regimen should be stated. It is not common to perform advanced
chemotherapy in all Stage II cases.
3) Tables 1, 2, 3. Not only the classification of Colon and Rectum, but also the sideness of colon
should be classified.
4) Table 2. It is strange that colon and rectum are not prognostic factors.
5) Discussion. From Table 1, mSEPT9 and microsatellite status seem to be closely related, but
that is not discussed.
6) Discussion. The limitation of this study is not mentioned.
Minor point
7) 2.1 Patients, exclusion criteria, (III). No adjuvant treatment # neoadjuvant treatment
Please review this paper.
user
Title: Methylated septin 9 gene is an important prognostic marker in stage II and stage III
colorectal cancer for evaluating local recurrence or distant metastasis after surgery
Version: 1 Date: 15 Nov 2021
Reviewer's report:
Major points
1) 2.1 Patients, line 2. Two-year DFS has been analyzed even though the end of the case
enrollment period is January 2020, which is less than two years. The Median follow up period
should be indicated. Also, in Figure 4, Patients at risk should be shown.
2) The Adjuvant chemotherapy regimen should be stated. It is not common to perform advanced
chemotherapy in all Stage II cases.
3) Tables 1, 2, 3. Not only the classification of Colon and Rectum, but also the sideness of colon
should be classified.
4) Table 2. It is strange that colon and rectum are not prognostic factors.
5) Discussion. From Table 1, mSEPT9 and microsatellite status seem to be closely related, but
that is not discussed.
6) Discussion. The limitation of this study is not mentioned.
Minor point
7) 2.1 Patients, exclusion criteria, (III). No adjuvant treatment # neoadjuvant treatment
assistant